1NA, together with Kristina Ganzinger’s group at AMOLF and Oncode, secured €200,000 to expand NanoLoom for the study of genome-related conditions. The project aims to develop advanced DNA-PAINT labelling strategies that extend the imaging window for observing protein-DNA binding, broadening the platform’s ability to study genome-associated processes at the single-molecule level.

1NA, together with Geraldine Farge’s group at LPCA, received €120,000 to expand NanoLoom for the discovery of treatments for mitochondrial disorders. The project focuses on studying and validating compounds that enhance the activity of the mitochondrial polymerase POLG, supporting the development of new therapeutic strategies for POLG-related disease.

1NA, together with Jorine Eeftens’ group at Radboud University, was awarded €428,135 to expand NanoLoom for the discovery of transcription factor-targeting drugs in cancer. The project will enable high-throughput single-molecule screening of compounds that modulate the androgen receptor. The work also includes the development of AI-driven data analysis tools to accelerate drug discovery.

1NA, together with SCIL Nanoimprint Solutions, obtained €199,353 to scale the production of NanoLoom chips. The project focuses on developing a cost-effective manufacturing process based on nanoimprint lithography, enabling the large-scale production of the nanostructured components required for DNA curtains technology.

1NA, together with ProPharma Japan, secured €60,000 to accelerate the adoption of NanoLoom in Japan. The project focuses on assessing regulatory and commercial opportunities, engaging key stakeholders, and demonstrating the technology to potential users and partners across the Asia-Pacific region.

1NA, together with Meindert Lamers’ group at LUMC, was awarded €450,000 to expand NanoLoom with advanced structural imaging capabilities. The project combines NanoLoom single-molecule imaging with cryo-electron microscopy to characterize drug-target interactions and study DNA replication inhibitors. A key application is the investigation of the Mycobacterium tuberculosis replisome to support the development of new antimicrobial therapies.

1NA, together with a consortium of five European companies, secured €1,000,726 to transform NanoLoom into a fully integrated drug discovery platform. The project combines NanoLoom screening technology, automated experimental workflows, and AI-based data analysis to create a scalable solution for drug discovery in both academic and pharmaceutical research environments.